Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence.
Animals
Anti-Inflammatory Agents
/ pharmacology
Cannabidiol
/ pharmacology
Cannabinoid Receptor Agonists
/ pharmacology
Cannabinoids
/ pharmacology
Disease Models, Animal
Dronabinol
/ pharmacology
Drug Evaluation, Preclinical
Eye Pain
/ drug therapy
Leukocytes
/ drug effects
Lipid Metabolism
/ drug effects
Rodentia
Uveitis
/ drug therapy
CB1R
CB2R
Cannabinoids
Endocannabinoid system
Ocular chronic pain
Ocular inflammatory pain
Ocular neuropathic pain
Ocular pain models
Systematic review
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
11
10
2021
revised:
26
11
2021
accepted:
03
12
2021
pubmed:
11
12
2021
medline:
17
3
2022
entrez:
10
12
2021
Statut:
ppublish
Résumé
Purpose of the present systematic review is to investigate preclinical evidence in favor of the working hypothesis of efficacy of cannabinoids in ocular pain treatment. Literature search includes the most relevant repositories for medical scientific literature from inception until November, 24 2021. Data collection and selection of retrieved records adhere to PRISMA criteria. In agreement with a priori established protocol the search retrieved 2471 records leaving 479 results after duplicates removal. Eleven records result from title and abstract screening to meet the inclusion criteria; only 4 results are eligible for inclusion in the qualitative synthesis impeding meta-analysis. The qualitative analysis highlights the antinociceptive and anti-inflammatory efficacy of Δ8-tetrahydrocannabinol, cannabidiol and its derivative HU-308 and of new racemic CB1 allosteric ligand GAT211 and its enantiomers GAT228 and GAT229. Moreover, CB2R agonists RO6871304 and RO6871085 and CB2R ligand HU910 provide evidence of anti-inflammatory efficacy. CB2 agonist HU308 reduces of 241% uveitis-induced leukocyte adhesion and changes lipidome profile. Methodological and design issues raise concern of risk of bias and the amount of studies is too small for generalization. Furthermore, the ocular pain model used can resemble only inflammatory but not neuropathic pain. The role of the endocannabinoid system in ocular pain is underinvestigated, since only two studies assessing the effects of cannabinoid receptors modulators on pain behavior and other two on pain-related inflammatory processes are found. Preclinical studies investigating the efficacy of cannabinoids in ocular inflammatory and neuropathic pain models are needed to pave the way for clinical translation.
Sections du résumé
BACKGROUND
BACKGROUND
Purpose of the present systematic review is to investigate preclinical evidence in favor of the working hypothesis of efficacy of cannabinoids in ocular pain treatment.
METHODS
METHODS
Literature search includes the most relevant repositories for medical scientific literature from inception until November, 24 2021. Data collection and selection of retrieved records adhere to PRISMA criteria.
RESULTS
RESULTS
In agreement with a priori established protocol the search retrieved 2471 records leaving 479 results after duplicates removal. Eleven records result from title and abstract screening to meet the inclusion criteria; only 4 results are eligible for inclusion in the qualitative synthesis impeding meta-analysis. The qualitative analysis highlights the antinociceptive and anti-inflammatory efficacy of Δ8-tetrahydrocannabinol, cannabidiol and its derivative HU-308 and of new racemic CB1 allosteric ligand GAT211 and its enantiomers GAT228 and GAT229. Moreover, CB2R agonists RO6871304 and RO6871085 and CB2R ligand HU910 provide evidence of anti-inflammatory efficacy. CB2 agonist HU308 reduces of 241% uveitis-induced leukocyte adhesion and changes lipidome profile. Methodological and design issues raise concern of risk of bias and the amount of studies is too small for generalization. Furthermore, the ocular pain model used can resemble only inflammatory but not neuropathic pain.
CONCLUSIONS
CONCLUSIONS
The role of the endocannabinoid system in ocular pain is underinvestigated, since only two studies assessing the effects of cannabinoid receptors modulators on pain behavior and other two on pain-related inflammatory processes are found. Preclinical studies investigating the efficacy of cannabinoids in ocular inflammatory and neuropathic pain models are needed to pave the way for clinical translation.
Identifiants
pubmed: 34891121
pii: S0753-3322(21)01291-9
doi: 10.1016/j.biopha.2021.112505
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Cannabinoid Receptor Agonists
0
Cannabinoids
0
Cannabidiol
19GBJ60SN5
Dronabinol
7J8897W37S
HU 308
8I5L034D55
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
112505Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.